Literature DB >> 7296751

Fluorescence assays and pharmacokinetic studies of 4'-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors.

F Formelli, C Pollini, A M Casazza, A di Marco, A Mariani.   

Abstract

The pharmacokinetic of 4'-deoxydoxorubicin, a new analog of doxorubicin, was compared with that of its parent compound in mice treated with equal and equiactive doses. The levels of total fluorescence due to the initial drugs and to metabolites were determined in tissue extracts by fluorometry. 4'-Deoxydoxorubicin reached the same tissue levels as doxorubicin in all the organs tested except in spleen and lung, where a higher peak was found in the animals treated with the new analog. The rate of elimination of 4'-deoxydoxorubicin from the organs tested was higher than that of doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7296751     DOI: 10.1007/bf00258470

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Synthesis and antitumor activity of 4'-deoxydaunorubicin and 4'-deoxyadriamycin.

Authors:  F Arcamone; S Penco; S Redaelli; S Hanessian
Journal:  J Med Chem       Date:  1976-12       Impact factor: 7.446

2.  Biologic characterization and chemotherapeutic response of MS-2 tumor: a non-regressing mouse sarcoma derived from MSV-M-induced sarcoma.

Authors:  F Giuliani; O Bellini; A M Casazza; F Formelli; G Savi; A Di Marco
Journal:  Eur J Cancer       Date:  1978-05       Impact factor: 9.162

3.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

4.  A fluorometric assay for daunomycin and adriamycin in animal tissues.

Authors:  H S Schwartz
Journal:  Biochem Med       Date:  1973-06

5.  Comparative pharmacokinetics of daunomycin and adriamycin in several animal species.

Authors:  D W Yesair; E Schwartzbach; D Shuck; E P Denine; M A Asbell
Journal:  Cancer Res       Date:  1972-06       Impact factor: 12.701

6.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.

Authors:  N R Bachur; A L Moore; J G Bernstein; A Liu
Journal:  Cancer Chemother Rep       Date:  1970-04

7.  Adriamycin: toxicity data.

Authors:  C Bertazzoli; T Chieli; M Grandi; G Ricevuti
Journal:  Experientia       Date:  1970-04-15

8.  Changes of activity of daunorubicin, adriamycin and stereoisomers following the introduction or removal of hydroxyl groups in the amino sugar moiety.

Authors:  A Di Marco; A M Casazza; T Dasdia; A Necco; G Pratesi; P Rivolta; A Velcich; A Zaccara; F Zunino
Journal:  Chem Biol Interact       Date:  1977-12       Impact factor: 5.192

9.  Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.

Authors:  F Formelli; A M Casazza; A Di Marco; A Mariani; C Pollini
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  9 in total
  9 in total

Review 1.  Anthracycline analogs: the past, present, and future.

Authors:  R B Weiss; G Sarosy; K Clagett-Carr; M Russo; B Leyland-Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Phase I trial with 4'-deoxydoxorubicin (esorubicin).

Authors:  M Rozencweig; N Crespeigne; Y Kenis
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

3.  Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.

Authors:  H Iguchi; H Tone; T Ishikura; T Takeuchi; H Umezawa
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 4.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

5.  Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin).

Authors:  P Dodion; T A Davis; M Rozencweig; N Crespeigne; Y Kenis; N R Bachur
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

6.  Effect of amrinone on anthracycline-induced lethal and cardiac toxicity in mice and rats.

Authors:  F Villani; C Manzotti; M Mella; E Monti; G Savi; F Zunino
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

7.  Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes.

Authors:  A Rahman; A Ganjei; J R Neefe
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  Phase I study with 4'-deoxydoxorubicin.

Authors:  L Ferrari; A Rossi; C Brambilla; V Bonfante; F Villani; F Crippa; G Bonadonna
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

9.  Comparative pharmacokinetics and metabolism of doxorubicin and 4-demethoxy-4'-O-methyldoxorubicin in tumor-bearing mice.

Authors:  F Formelli; R Carsana; C Pollini
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.